glp 1 agonist parkinson Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment Neuroprotective effects of GLP-1 class

The above clinical studies will have implications on the guideline development including the treatment of T2DM and obesity in young people and balancing the cost with the efficacy of the emerging therapies

doi: 10.1111/dom.13911 56 AhrenBHirschIBPieberTRMathieuCGomez-PeraltaFHansenTKet al

The MHRA opened a formal investigation in 2025 (O'Dowd, 2025)

Over time, some of these agents (in particular, GLP-1 agonists and SGLT2 inhibitors), which were initially developed for their glucose-lowering actions, have demonstrated significant beneficial pleiotropic effects, thus expanding their potential therapeutic applications

doi: 10.1038/304368a0 [DOI] [PubMed] [Google Scholar] 18

It is not widely prescribed